TuHURA Biosciences (HURA) to Release Earnings on Tuesday

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) will likely be releasing its earnings data before the market opens on Tuesday, May 13th. Analysts expect TuHURA Biosciences to post earnings of ($0.14) per share for the quarter.

TuHURA Biosciences Stock Up 1.0 %

Shares of HURA stock traded up $0.04 during trading hours on Friday, reaching $3.97. The company had a trading volume of 90,740 shares, compared to its average volume of 252,910. TuHURA Biosciences has a 1-year low of $1.80 and a 1-year high of $7.93. The firm's 50 day simple moving average is $3.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TuHURA Biosciences stock. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 14,314 shares of the company's stock, valued at approximately $59,000. Institutional investors and hedge funds own 0.62% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price target on shares of TuHURA Biosciences from $13.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, April 3rd.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.